

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF
1934

August 31, 2021

001-36686
(Commission file number)

Forward Pharma A/S
(Translation of registrant's name into English)

Østergade 24A, 1st Floor
1100 Copenhagen K, Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes No

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A

Item 1. Other Items

Forward Pharma A/S (the “Company”) is submitting this Report on Form 6-K to provide its (i) interim condensed consolidated statement of financial position as of June 30, 2021, unaudited, and December 31, 2020 and (ii) unaudited interim condensed consolidated statements of profit or loss for each of the six-month periods ended June 30, 2021 and 2020, which are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively. Exhibits 99.1 and 99.2 are furnished herewith solely for the purpose of meeting the requirements of Nasdaq Stock Market Rule 5250(c)(2) to submit an interim balance sheet and income statement as of the end of the Company’s second quarter.

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
<u>99.1*</u>	<u>Interim condensed consolidated statement of Financial Position of the Company as of June 30, 2021, unaudited, and December 31, 2020</u>
<u>99.2*</u>	<u>Unaudited interim condensed consolidated statement of Profit or Loss of the Company for each of the six-month periods ended June 30, 2021 and 2020</u>

* Furnished herewith solely for the purpose of meeting the requirements under Nasdaq Stock Market Rule 5250(c)(2) in connection with submission of an interim balance sheet and income statement as of the end of the Company’s second quarter.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Date: August 31, 2021

Forward Pharma A/S

By: /s/ Claus Bo Svendsen

Name: Claus Bo Svendsen

Title: Chief Executive Officer

Interim Condensed Consolidated Statement of Financial Position

as of June 30, 2021, Unaudited, and December 31, 2020

Assets

	June 30, 2021 (Unaudited)	December 31, 2020
	USD `000	USD `000
Non-current Assets:		
Other non-current assets	3	3
Total non-current assets	3	3
Prepaid expenses	224	337
Other receivables	182	91
Income tax receivable	190	196
Cash and cash equivalents	75,097	79,087
Total current assets	75,693	79,711
Total assets	75,696	79,714

Equity and Liabilities

	June 30, 2021 (Unaudited)	December 31, 2020
	USD `000	USD `000
Share capital	157	154
Other components of equity:		
Foreign currency translation reserve	90,808	93,315
Accumulated deficit	(15,856)	(14,825)
Equity attributable to shareholders of the Parent	75,109	78,644
Total equity	75,109	78,644
Trade payables	30	476
Accrued liabilities	557	594
Total current liabilities	587	1,070
Total equity and liabilities	75,696	79,714

Unaudited Interim Condensed Consolidated Statement of Profit or Loss

for the six-month periods ended June 30, 2021 and 2020

amounts in thousands except per share amounts

	Six Months Ended June 30,	
	2021 USD	2020 USD
Research and development costs	(63)	(235)
General and administrative costs	(1,761)	(1,788)
Operating loss	(1,824)	(2,023)
Foreign exchange rate gain (loss), net	893	(240)
Other finance (expense) income, net	(101)	4
Net loss for the period	<u>(1,032)</u>	<u>(2,259)</u>
Net loss for the period attributable to:		
Equity holders of the Parent	<u>(1,032)</u>	<u>(2,259)</u>
Net loss per share basic and diluted	<u>(0.01)</u>	<u>(0.02)</u>